Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?

Chronic lymphocytic leukaemia (CLL) is an extremely heterogeneous disease in terms of its clinical course and a variety of biomarkers have been described that have powerful prognostic and predictive outcome. An important question is how can this be added to by the more recent identification of recurrent genetic mutations in CLL. In the current paper, (Hu et al., 2019) the authors studied the impact on time from diagnosis to time to first...